Dr Reddy’s Laboratories, alongside its division Aurigene Pharmaceutical Services, has entered into a non-binding memorandum of understanding (MoU) with US-based Kainomyx to co-develop and co-commercialise an affordable anti-malarial drug. The collaboration aims to address the needs of patients in Europe, the US, and low and middle-income countries. The gold standard of business intelligence.
The MoU, which is pending a definitive agreement, outlines a shared commitment to driving a comprehensive research and development agenda. By leveraging the unique strengths of each partner, the collaboration will expedite the development programme for this new anti-malarial treatment. Kainomyx will offer a platform that targets the cytoskeletal proteins of parasites, representing a new mechanism of action in the fight against malaria.
Dr.Reddy’s Laboratories API [active pharmaceutical ingredients] and services CEO Deepak Sapra said: “Public health and access is a strategic area for us and malaria continues to be a very important disease that needs innovative as well as affordable medicines. Access the most comprehensive Company Profiles on the market, powered by GlobalData.
Save hours of research. Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles.
However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form “Th.